Posters

Impact of Psoriasis Area and Severity Index (PASI)
Association between disease severity and body mass index
Patients at Risk for Psoriatic Arthritis Among Those With Psoriasis
Impact of Psoriasis Severity on Patient-reported Clinical Symptoms, QoL and Work Productivity

Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry

Summary:
•Psoriasis (PsO) is an immune mediated chronic inflammatory disease, which has significant impact on health related quality of life (HRQoL). Disease severity and assessment of patient reported outcomes (PROs) has become increasingly important for defining effective treatment options. •The objective of this study is to examine the association between disease severity measured by Psoriasis Area and Severity Index (PASI) and patient reported outcomes (PROs) at enrollment in the Corrona Psoriasis Registry, a prospective observational cohort of PsO patients.
Authors:
Bruce Strober, Chitra Karki, Marc Mason, Jeffrey D Greenberg, Mark Lebwohl
PDF icon Download (936.84 KB)

Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry

Summary:
•Recent studies have shown strong association between obesity and psoriasis (PsO) disease activity that may lead to implications in disease management. •The objective of this study is to examine the association between body mass index (BMI) (an index for adiposity) and PsO disease severity in an observational cohort of PsO patients.
Authors:
Bruce Strober, Chitra Karki, Marc Mason, Jeffrey D Greenberg, Mark Lebwohl
PDF icon Download (801.49 KB)

Patients at Risk for Psoriatic Arthritis Among Those With Psoriasis: Analysis From the Corrona Psoriasis Registry

Summary:
•Undiagnosed psoriatic arthritis (PsA) remains high in patients with psoriasis (PsO); a meta-analysis reported that between 10.1%and 15.5% of patients with PsO seen by dermatologists in hospital settings may have undiagnosed PsA o In a large, observational cohort of 1511 patients with PsO in Germany, 20.6% of patients had PsA, which was newly diagnosed in 85% of cases o Of 949 patients with PsO evaluated at 34 dermatology centers across 7 countries in North America and Europe, 285 (30%) had PsA, 117 (41%) of whom were not previously diagnosed •A delay in PsA diagnosis contributes to development of peripheral joint erosions and worse long-term physical function •Screening tools like the Psoriasis Epidemiology Screening Tool (PEST) may be helpful in aiding diagnosis in a dermatology clinic setting
Authors:
Philip J. Mease, MD, Jacqueline B. Palmer, PharmD, Bruce E. Strober, MD, PhD, Mark Lebwohl, MD, PhD, Chitra Karki, MPH, George W. Reed, PhD, Carol J. Etzel, PhD, Jeffrey D. Greenberg, MD, MPH, Philip S. Helliwell, MD, PhD
PDF icon Download (450.35 KB)

Impact of Psoriasis Severity on Patient-reported Clinical Symptoms, Health-related Quality of Life, and Work Productivity Among US Patients: Real-world Data From the Corrona Psoriasis Registry

Summary:
•Psoriasis is a chronic, immune-mediated disease, with key clinical symptoms including skin itching, pain, and fatigue •Previous studies have reported that increased psoriasis severity is associated with worsened patient quality of life (QoL) and reduced work productivity1-5;however, few studies have examined how the severity measures used in clinical trials are associated with QoLin the real-world setting: oOne example of such a severity measure is the Investigator’s Global Assessment (IGA) mod 2011, which has been used in clinical trials7 oAffected body surface area (BSA) is a severity measure that is widely used by physicians •The objective of this study is to gain a better understanding of the relationship between disease severity in terms of IGA and BSA and patient-reported outcomes in a real-world setting
Authors:
B. Strober, J.D. Greenberg, C. Karki, M. Mason, N. Guo, P. Hur, Y. Zhao, V. Herrera, F. Lin, M. Lebwohl
PDF icon Download (439.28 KB)

Pages